Rani Jarkas: China’s renminbi internationalization efforts deliver concrete advances

China has been pushing for yuan‘s global use, as the world’s largest trading nation looks to lower transaction cost in international trade, which is mostly settled in US dollars at present. Renminbi has joined the ranks as one of the most-widely used currencies in global markets.

CNBC reports that the renminbi stands as the world’s largest trade-finance currency after the US dollar. China’s currency is expected to surpass the Japanese yen as the world’s 4th-most used international currency.

Data released by the International Monetary Fund (IMF) showed that in 2014 the renminbi had accounted for 2.96 percent of worldwide trades, along with total direct investments valued at US$ 1.05 trillion.

Moreover, $94 billion of official assets were already held in renminbi at the end of 2014, accounting for 1.1 percent of global foreign exchange reserves.

The IMF last year agreed to include renminbi into its Special Drawing Rights (SDR) currency basket, as a clear representation of the reforms in China.

Last week, the Monetary Authority of Singapore (MAS) announced that it will include renminbi investments as part of its official foreign reserves from June.

Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of financial experience in Asia, said, “As China plays an increasingly important role on the international stage, RMB is becoming truly global and this is set to continue.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

王雷（Rani Jarkas）：中国的人民币全球化努力取得实效

中国正在推进人民币在全球范围内的使用。这个世界最大的贸易国希望通过这一手段降低目前主要由美元结算的国际贸易交易成本。人民币已成为全球市场上最广泛使用的货币之一。

美国消费者新闻与商业频道（CNBC）报道人民币是除美元外世界最大的贸易金融货币。中国货币有望将超越日元成为世界第四大最常用的国际货币。

国际货币基金组织的数据显示2014年人民币占到全球贸易的2.96%，直接投资总额达到1万亿美元。

另外，2014年，人民币官方储备资产已达940亿美元，占到全球外汇储备的1.1%。

国际货币基金组织去年同意把人民币纳入特别提款权一篮子货币，更展示了中国改革的成功。

上周，新加坡金融管理局宣布从6月起将人民币投资加入官方外汇储备。

赛德思投资董事长王雷（Rani Jarkas）在亚洲有多年的金融投资经验。他表示：“随着中国在国际舞台上扮演着日益重要的角色，人民币将实现真正的全球化，并且这一状况将持续下去。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

Rani Jarkas: Cross-border Partnerships, M&A and VC Investment Thrive in China Life Science

China has declared it wants to be the world’s leader in drug innovation, and its life science sector made remarkable progress toward becoming a global leader in 2016. With China’s thirteenth Five-Year Plan reinforcing the country’s focus on “biological technology”, the cross-border partnerships, M&A and VC investment in China’s life science industry is set to boom.

Research also shows that most of the deal making activity was in support of drug development and commercialization. In 2015, striking deals for pharma assets has become a primary means of leveraging the burgeoning China market, which is now the number two pharmaceutical market in the world.

“In the world of China life science, VC investment, M&A transactions, partnering activity, especially cross-border deals – all of these metrics were up substantially last year,” said Greg B. Scott, CEO and Founder of ChinaBio? LLC, a consulting and advisory firm based in Shanghai.

One of the most remarkable things about this trend is that innovative SMEs are vital for the development of new products and services in the field of life sciences and medical technology.

Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in biotech and life science sector, said, “Innovation is complex and not all the necessary expertise, facilities and funding are available in each company’s region. China’s pursuit of life science development will drive Chinese healthcare SMEs to seek cross-border collaboration in the global scope.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

王雷（Rani Jarkas）：生物医药跨境合作、并购和风险投资在中国蓬勃发展

中国已宣布了成为药物创新全球领军人物的目标，并且中国在2016年已取得了令人瞩目的进步。随着“十三五”计划的发布再次强调了国家重点发展“生物科技”的战略，中国生命科学产业的跨境合作、并购和风险投资开始进入繁荣时代。

研究也表明大多数的交易活动都推动了药物发展和商业化。2015年，制药领域引人瞩目的交易都成为借助中国这一生机勃勃的全球第二大药品市场的主要方式。

总部在上海的咨询顾问公司ChinaBio?创始人兼执行总裁Greg B. Scott先生表示，“在中国生命科学领域，风险投资、并购交易和合作活动，特别是跨境交易，都在去年取得了显著增加”。

值得注意的是，创新中小型企业在生命科学和医疗技术领域对新产品和服务的发展是至关重要的。

赛德思投资董事长王雷（Rani Jarkas）在生物科技领域有多年的投资经验。他表示：“创新本身是复杂的，在一国之内很难拥有所有必需的专业知识、设施和资金。中国对生命科学发展的追求将推动中国中小型医药企业在全球范围内寻求跨境合作。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

Rani Jarkas: China pays great attention to youth football development

According to “The Mid- and Long-Term Development Plan for Chinese Soccer” issued in April by China’s National Development and Reform Commission, China aims to rank among the world top teams by 2050.

“By 2020, China will have 20,000 soccer academies. Chinese football teams, for both men and women, will present impressive results in World Cup, Asian Cup and Olympics,” the plan added.

Li Shuyi, Executive Deputy Director at the inter-ministerial joint conference office specializing in the country’s football development, believed a lot more needs to be done in order to make virtual progress in the sport. “We need to build a world-class backup system in Chinese national team operation”, said Li.

Most of all, China had embarked the youth football development program, aiming to dig deep on grassroots football. The development will be accelerated in schools. Schools with a specialty in football will expand from the current number of 5,000 to 20,000 by 2020 and further increase to 50,000 by 2025. There will be over 30 million primary and middle school students who often play soccer.

Rani Jarkas, Chairman of Cedrus Investments, who is also concerned about the development of China’s football, said, “Football academies are the motive force of the constant development of football. The future of China’s football will benefit greatly from its youth football development program.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

王雷（Rani Jarkas）：中国将成为世界科技强国

5月30日，在全国科技创新大会、中国科学院第十八次院士大会和中国工程院第十三次院士大会上，中国国家主席习近平发表讲话，指出我国科技事业发展的目标是到本世纪中叶成为世界科技强国。

 

习近平指出，中国到2020年时应进入创新型国家行列，到2030年时进入创新型国家前列，到2049年新中国成立100年时，应成为世界科技强国。

 

该战略旨在确保中国自我发展的决策能力，提高核心竞争力，加快转变经济发展方式，破解经济发展深层次矛盾和问题，更好引领中国经济发展新常态，保持经济持续健康发展。

 

在过去的30年中，中国经济发展的30%来自创新。然而，发达国家的数字达到70%。国家信息中心经济预测部专家祝宝良表示，由于面临的人口结构问题，例如社会迅速老龄化和隐约可见的劳动力短缺，中国不能持续依靠人力投入来发展经济。

 

今年早些时候，国家总理李克强承诺，随着中国致力于创新发展并成为世界科技强国，科技领域将会获得更多的自由和财政支持。

 

李克强总理在此次活动上表示，中国的整体研发支出将持续增加，从目前占国内生产总值的2.1%，将在2020年攀升到2.5%。

 

赛德思投资董事长王雷（Rani Jarkas）在科技领域有多年的投资经验。他表示：“创新是推动一个国家发展的根本动力。我相信中国将有能力在可预见的未来成为世界科技的主要强国。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

Rani Jarkas: Cross-border innovation and investment in China’s life science industry

As China’s economy continues to surge and move up the product cycle, the country is on track to become a global leader in life sciences innovation and manufacturing. Foreign firms, which hold a 30 percent share of the local market, are rapidly expanding their biotech investments in China – in manufacturing, joint ventures, and R&D — yet they continue to face many challenges.

With the recently announced positive regulatory and compliance policy reforms, China’s life science industry is set to boom. Released in March 2016, China’s thirteenth Five-Year Plan reinforces the country’s focus on “innovative development” with additional emphasis on “biological technology.”

Besides domestic innovation, entrepreneurs in the field have also created cross-border business models, including investments in global clinical stage candidates and international collaborations for the best efficiency.

China continues to be a hotbed for partnering activity, more than doubling in 2015 to over US$4 billion in total announced deal value. Traditionally, Chinese partners tend to contribute heavily on infrastructure and other local resources performing a more “CRO-oriented” role. However, there has also been a rise in Chinese biotechs with truly innovative drug candidates that have attracted the attention of foreign pharms.

Cross-border partnership is developing a network across academics, business and clinicians to drive innovation in China’s healthcare industry. The ultimate objective is to improve treatments, diagnoses and quality of life for patients in China but will also lead to a huge number of business opportunities and will develop China’s capabilities as an innovation destination.

Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in biotech and life science sector, said, “China’s pursuit of a domestic life science sector will benefit the Chinese people, local entrepreneurs, and multinationals who are hungry to identify solutions designed to reflect China’s unique healthcare challenges.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

 

王雷（Rani Jarkas）：中国生物科技产业的跨境创新和投资

随着中国经济持续飞速发展，并在产品周期循环内向上移动，整个国家正在成为生命科学创新和生产领域的全球领导者。外国公司在本土市场占到约30%，也正在加速在中国的生物科技投资——在生产、合资企业和科研方面——但目前也仍然面临许多挑战。

中国近期公布了有利的监管和合规政策改革，推动了生命科学产业的蓬勃发展。2016年3月发布的中国“十三五”计划，再次强调了国家的重心是在“创新发展”，格外关注“生物科技”。

除了国内的创新，该领域的企业家们也开创了众多跨境交易模式，包括投资全球临床阶段产品和全球合作，以期获得最佳的效果。

中国继续成为合作活动的热点地区，2015年的交易额翻了一番，达到了40亿美元。传统意义上，中国合作者通常主要贡献在基础设施和其他当地资源，更多地担任了“临床研究机构”的角色。然而，中国的生物科技领域出现了一批真正的创新药物产品，吸引了国际药企的关注。

跨境合作正在学术研究机构、商业和临床医生间建立起网络，推动中国医疗产业的创新。最终的目标是提高中国的治疗、诊断和病人生活质量，但同时也会创造出数量庞大的商业机会，发展中国成为创新集聚地的能力。

赛德思投资董事长王雷（Rani Jarkas）在生物科技领域有多年的投资经验。他表示：“中国对国内生命科学产业的追求将造福于中国人民、本土企业以及那些公司渴望寻找到中国医疗独特挑战解决方案的跨国公司。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas